We’re seeking knowledgeable members for the following 2025 APC standing committees. If you have ideas you want to share and develop to enhance the future of compounding, here’s where you start. Committee terms run from Jan. 1 to Dec. 31, 2025, and all committee appointments must be approved by the APC Board of Directors. If you would like to be considered for appointment, click below, then fill out and submit the interest form by Nov. 30, 2024 at 5:00 pm EST. Submission of the interest form does not guarantee a committee appointment. https://ow.ly/MVny50UbhiS
Alliance for Pharmacy Compounding
非盈利组织
Alexandria，VA 4,816 位关注者
We're the voice for pharmacy compounding and the advocate for thousands of compounding professionals and their patients.
关于我们
We're the voice for pharmacy compounding and the advocate for thousands of compounding professionals and their patients. Our members are more than 500 businesses, including compounding pharmacists and technicians in both 503A and 503B settings, as well as prescribers, educators, researchers, and suppliers. In traditional compounding, pharmacists create a customized medication, most often from pure ingredients, for an individual patient pursuant to a prescription. Pharmacists’ ability to compound medications from pure ingredients is authorized in federal law and for good reason: Manufactured drugs don’t come in strengths and dosage forms that are right for everyone, and prescribers need to be able to prescribe customized medications when, in their judgment, a manufactured drug is not the best course of therapy for a human or animal patient. Every day, APC members play a critical role in patients’ lives, preparing essential, custom medications for a range of health conditions, including autism, oncology, dermatology, ophthalmology, pediatrics, women’s health, animal health, and others.
- 网站
-
https://a4pc.org
Alliance for Pharmacy Compounding的外部链接
- 所属行业
- 非盈利组织
- 规模
- 2-10 人
- 总部
- Alexandria，VA
- 类型
- 非营利机构
- 创立
- 1991
- 领域
- Compounding、Pharmacy、Advocacy、cBHRT、cBHT、Compounded hormones、503A和503B
地点
Alliance for Pharmacy Compounding员工
动态
-
???? ???? ????
"Most interesting is the fact that it seemed to take … over two years to muster enough concern for patient safety that they think this molecule ought to be placed off limits," says Brunner, who heads the compounding pharmacist trade group. "Compounders have been preparing the drug for the past two, two and a half years under FDA guidance." (APC members Jennifer Burch, PharmD, CDCES, FNCAP, FAPC and Scott Welch are quoted here as well.) #compounding #pharmacycompounding #compoundedGLP1s Alliance for Pharmacy Compounding
-
APC's perspective continues to be well represented in news media, from major media outlets to smaller blogs and health-focused publications. Here’s a sampling from the past week or so: Inside Health Policy: https://ow.ly/n76e50Ubh0U Health: https://ow.ly/9Jez50Ubh0G Verywell Health: https://ow.ly/c1ww50Ubh0K Medical News Today: https://ow.ly/4aqa50Ubh0J CNN: https://ow.ly/kIGX50Ubh10 Pharmaceutical Executive Magazine: https://ow.ly/3oWG50Ubh0Q Specialty Pharmacy Continuum: https://ow.ly/MZzb50Ubh0I
-
-
Drugmakers are urging the FDA to prohibit compounded GLP-1s The FDA needs to hear from you and your patients NOW! Two years into the GLP-1 injectable shortage, drugmakers Eli Lilly and Novo Nordisk have asked the FDA to take emergency action to prohibit compounding of tirzepatide and semaglutide. Both companies sent letters to FDA asking that their API be added to the ‘demonstrably difficult to compound list.’ The fact is, millions of doses have been safely prepared and dispensed by compounding pharmacies across the U.S. during this shortage. GLP-1s are not particularly difficult for sterile compounding labs to prepare. APC is leading an effort to oppose the drugmakers’ request, and we need your help — whether your pharmacy compounds GLP-1 drugs or not. Take action today. Patient access to compounded drugs is at stake. https://lnkd.in/ec3QfSFg
-
-
As an alternative to individual membership, APC offers pharmacy/facility membership as an option for 503A pharmacies and 503B outsourcing facilities of any size. Join today: https://a4pc.org/pfm
-
-
No, said Kentucky’s attorney general, the state’s board of pharmacy cannot legally license pharmacists who live outside Kentucky. The BoP in May had proposed a rule that would have “require[d] any pharmacist working in another state and who provides services on a Kentucky citizen’s prescription to obtain a non-resident pharmacist license,” which would have made Kentucky the first state with such a requirement. https://ow.ly/4iwk50UamYq
-
-
The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. It’s an evening of learning, networking, and eating at the Staybridge Suites Scottsdale-Talking Stick. What you get: - Two hours of live CE on the benefits of low-dose naltrexone (learn the latest on dosing, safety, science and physiology) and restoring thyroid balance (including the most recent best practices on compounding with thyroid APls). - A briefing on current compounding issues, including GLP-1s - A great catered dinner - The chance to network with compounders in your area It’s all just $25 thanks to a generous grant from PCCA. If you’re in the area, you don’t want to miss it. Click here and register today! https://ow.ly/tKSm50U9wNz
-
-
Get the facts here about patient adverse events reporting and compounded GLP1s >>>
Novo's CEO's recent comments about adverse events reports associated with compounded semaglutide garnered headlines, but – surprise!? – omitted some essential context, including what FDA's adverse events reporting system is and is not. To tutor policymakers and others about FDA's Adverse Events Reporting System (and why that CEO's comments were selective at best), we've created this briefing document below. As ever, our aim is not so much to put a shine on compounding but to provide factual information about it and why it is necessary and authorized in state and federal law. As it relates to patient adverse events associated with compounded AND FDA-approved drugs, here are facts: a4pc.org/FAERSbrief (The image below is just a screenshot of the first page. The entire doc is 4 pages, available at the url here ^) #compounding #pharmacycompounding #compoundedGLP1s Alliance for Pharmacy Compounding National Community Pharmacists Association (NCPA)
-
-
This (!)
Semaglutide and tirzepatide are *not* demonstrably difficult to compound. FDA needs to hear from patients how drugmakers' absurd request that it prohibit compounding of GLP1s will affect their access to these life-enhancing medications that the drugmakers *still* aren't able to adequately supply. Direct patients to https://lnkd.in/eZhAzbhb, where they can learn more and send a message. Takes about two minutes. Oh, and please repost this message. (We've prepared a bag-stuffer you can download and share here: https://lnkd.in/euUNctPV ) #compounding #pharmacycompounding #compoundedGLP1s Alliance for Pharmacy Compounding
-
-
Our December 5 webinar will be here before you know it. Make sure you have your spot reserved for "Compounding for Special Populations", presented by Katherine Moutis. https://ow.ly/512q50U6sWw
-